Understand the source comparison
Sexual Function Restoration: PT-141 Mechanism vs PDE5 Inhibitors
PT-141 (bremelanotide) is a cyclic heptapeptide that functions as a melanocortin receptor agonist. Specifically targeting MC3R and MC4R in the hypothalamus and spinal cord. Unlike PDE5 inhibitors (sildenafil, tadalafil), which require intact vascular endotheli
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (bremelanotide) is a cyclic heptapeptide that functions as a melanocortin receptor agonist. Specifically targeting MC3R and MC4R in the hypothalamus and spinal cord. Unlike PDE5 inhibitors (sildenafil, tadalafil), which require intact vascular endothelium and nitric oxide signaling, PT-141 operates centrally to restore libido and arousal via melanocortin-mediated neurotransmitter modulation. This distinction matters in andropause research because age-related erectile dysfunction often has dual etiology: vascular insufficiency and central desire deficit. PT-141 addresses the latter, which TRT alone frequently fails to correct.
- A randomised controlled trial published in The Journal of Sexual Medicine found PT-141 administered subcutaneously at 1.75mg produced statistically significant improvements in desire, arousal, and subjective satisfaction in hypogonadal men who had not responded adequately to TRT. The response rate was 58% versus 32% placebo. Comparable to PDE5 inhibitor monotherapy but operating through an entirely separate pathway. The onset is slower (45–90 minutes) than sildenafil, but the duration extends to 6–8 hours, and crucially, PT-141's effect doesn't require sexual stimulation to manifest. The melanocortin pathway directly modulates baseline arousal tone.
- The blunt research question PT-141 answers: is age-related libido loss in andropause driven by low testosterone itself, or by hypothalamic melanocortin receptor desensitisation that occurs independently of circulating androgen levels? Preclinical models in aged male rodents have shown that melanocortin signaling declines with age even when testosterone is experimentally maintained at youthful levels, suggesting PT-141 targets a parallel degenerative pathway. One preparatory note: PT-141 induces transient nausea in approximately 40% of subjects during the first 2–3 administrations. This typically resolves with repeat dosing but should be accounted for in study protocols where compliance is critical.